Mereo BioPharma Group plc
MREO
$2.30
$0.177.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.05% | -21.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 60.70% | -26.50% | |||
| Operating Income | -60.70% | 26.50% | |||
| Income Before Tax | 53.03% | -22.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 53.03% | -22.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.03% | -22.41% | |||
| EBIT | -60.70% | 26.50% | |||
| EBITDA | -61.79% | 26.96% | |||
| EPS Basic | 53.29% | -13.12% | |||
| Normalized Basic EPS | 53.37% | -13.20% | |||
| EPS Diluted | 53.29% | -13.12% | |||
| Normalized Diluted EPS | 53.37% | -13.20% | |||
| Average Basic Shares Outstanding | 0.64% | 8.20% | |||
| Average Diluted Shares Outstanding | 0.64% | 8.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||